Is AbbVie (ABBV) a Buy Right Now?
A plain-English read on AbbVie stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
AbbVie is currently priced at $248.78. While the stock saw a daily change of -2.99%, it remains above its 200-day average of $229.74, which is a common gauge of long-term trend health. This suggests the broader path for the company is still pointing upward.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far, too fast—is at 40.4. This level is considered neutral, meaning the stock is neither over-bought nor over-sold. With the price near the recent support floor of $248.86, the data supports a buy position.
Should you buy AbbVie stock?
The data indicates a buy because the stock maintains its long-term upward trend despite recent dips. You should buy only if your strategy aligns with holding through short-term price fluctuations. Always remember that buying is a personal choice based on your own risk tolerance.
Is ABBV a good stock for beginners?
AbbVie is a large, established company, which can offer more stability than smaller, unproven businesses. However, with a P/E ratio—a measure of how much you pay for each dollar of earnings—of 108.2, investors are paying a premium for these shares. Expect some volatility as the price moves within its 52-week range.
What's driving ABBV right now
The stock price of $248.78 remains comfortably above the 200-day average of $229.74.
The current price is sitting right near the recent support level of $248.86.
The P/E ratio of 108.2 suggests that the market is currently pricing the stock at a high multiple of its earnings.
The current price is currently trading below the 50-day average of $255.19.
What AbbVie actually does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie by the numbers
Wall Street consensus on ABBV is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
AbbVie's earnings history
Earnings per share for AbbVie's last 4 reported financial years, as filed — EPS has fallen over that span. We don't hold analyst consensus estimates for these periods, so no beat-or-miss judgement is shown.
| Period end | EPS reported |
|---|---|
| 2025-12-31 | 2.37 |
| 2024-12-31 | 2.40 |
| 2023-12-31 | 2.73 |
| 2022-12-31 | 6.65 |
Who owns AbbVie?
Institutions — pension funds, asset managers, index providers — hold 77.5% of ABBV, and the concentration matters: the largest single holder alone controls 8.46% of the company.
| Holder | Shares | % held |
|---|---|---|
| 149.49M | 8.46% | |
| 115.40M | 6.53% | |
| 82.60M | 4.67% |
Names withheld — plus 3 more records not shown.
See who owns itWhat AbbVie insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for AbbVie, 1 was a sale and 0 were open-market purchases; the other 5 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-14 | SELL | 32.7K | $8.2M | |
| 2026-08-14 | AWARD / VEST | 32.7K | $2.6M | |
| 2026-05-08 | AWARD / VEST | 1.1K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading ABBV?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name ABBV — filed by 9 separate members or more and worth $123K–$545K combined (filings report bands, never exact amounts). 14 purchase-side, 11 sale-side, most recently on 2026-05-05.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2025-12-18 | SELL | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersAbbVie is a buy because it holds its long-term trend above the 200-day average, providing a solid foundation for patient investors.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice ABBV risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about ABBV
Should I buy ABBV stock?+
The data supports a buy rating as the stock remains above its 200-day average of $229.74.
Is ABBV a good long-term investment?+
The long-term trend is positive, as the price is currently above the 200-day average of $229.74.
Is ABBV a buy or a sell?+
Based on the current data and the stock holding its support level of $248.86, the verdict is a buy.
Is ABBV overvalued?+
With a P/E ratio of 108.2, the stock is trading at a high valuation relative to its current earnings.
Is ABBV a good stock for beginners?+
It is a large company, but beginners should note the P/E ratio of 108.2 and the 52-week range of $190.75 to $267.47.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold AbbVie (ABBV) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-09-08 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.